Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.

Chwee Ming LimAnthony LiouMichelle PoonLiang Piu KohLip Kun TanKwok Seng LohBengt Fredrik PeterssonEric TingDario CampanaBoon Cher GohNoriko Shimasaki

Published in: Cancer immunology, immunotherapy : CII (2022)

Engaging NK cell-mediated ADCC using cetuximab plus autologous NK cells in EGFR-positive NPC was well tolerated among heavily pre-treated recurrent NPC. Promising results were observed with 3 out of 7 subjects demonstrating durable stable disease.

Keyphrases

nk cells
natural killer cells
small cell lung cancer
metastatic colorectal cancer
squamous cell carcinoma
locally advanced
epidermal growth factor receptor
bone marrow
tyrosine kinase
wild type
cell therapy
platelet rich plasma
mesenchymal stem cells